Fig. 7: Anti-tumor immunity induced by necroptotic dying cells is abrogated with loss of type I interferon signaling.

A WT, Casp8-KO, MLKL-KO, and DKO LLC-OVA cells were treated for 8 h with DOX (1 μg/mL) followed by treatment with MG132 (4 μM). After 4.5 hours of treatment with MG132, RNA was prepped using tumor cell lysates. Gene expression for Ifnb, Ifi44, and Ifit1 was assessed by qPCR as indicated. Each point represents an average of technical replicates from an individual experiment. B Dying cell immunization and subsequent live tumor challenge was performed in WT or Ifnar1^−/− mice. Data is aggregated from two independent experiments (n = 4–5 per treatment group per experiment). C Anti-IFNAR1 antibody or Isotype control was administered the day prior to necroptotic cell immunization. Live tumor challenge was performed 8 days post-immunization. Data is representative of three independent experiments (n = 3–5 per treatment group per experiment). D T cell infiltrate was assessed in tumors at day 14 post-tumor challenge in WT or Ifnar1^−/− mice. Data is aggregated from two independent experiments (n = 4–5 per treatment group per experiment). For A, D, treatment groups were compared using one-way ANOVA. For B, C, treatment groups were compared using two-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.